Episodes 1-15 of 235
Differentiating Biomarker-Driven First-Line Treatment Strategies in Metastatic Gastric/GEJ Cancers
CME/CE Live BroadcastDifferentiating Biomarker-Driven First-Line Treatment Strategies in Metastatic Gastric/GEJ Cancers
September 27, 2024
02:00 PM - 02:45 PM ET
Targeting Resistance in EGFRm NSCLC with HER3-Directed ADCs in the Community Setting
CME/CETargeting Resistance in EGFRm NSCLC with HER3-Directed ADCs in the Community Setting
Significance of HER2 Expression in Solid Tumors
MinuteCE®Significance of HER2 Expression in Solid Tumors
HER2 Testing Strategies Across Tumor Types Amidst Guidelines Gaps
MinuteCE®HER2 Testing Strategies Across Tumor Types Amidst Guidelines Gaps
Diversity in HER2 Expression Among Gynecologic Cancers
MinuteCE®Diversity in HER2 Expression Among Gynecologic Cancers
Pivotal Data on Targeting HER2 in HER2-Expressing Solid Tumors
MinuteCE®Pivotal Data on Targeting HER2 in HER2-Expressing Solid Tumors
Emerging Data Evaluating HER2-Directed Therapies in Gynecologic Cancers
MinuteCE®Emerging Data Evaluating HER2-Directed Therapies in Gynecologic Cancers
Monitoring and Managing Treatment-Related Adverse Effects Associated With HER2-Directed Agents
MinuteCE®Monitoring and Managing Treatment-Related Adverse Effects Associated With HER2-Directed Agents
Patient Case: How Do HER2-Directed Therapies Fit Into the Ovarian Cancer Treatment Landscape?
MinuteCE®Patient Case: How Do HER2-Directed Therapies Fit Into the Ovarian Cancer Treatment Landscape?
Patient Case: How Do HER2-Directed Therapies Fit Into the Biliary Tract Cancer Treatment Landscape?
MinuteCE®Patient Case: How Do HER2-Directed Therapies Fit Into the Biliary Tract Cancer Treatment Landscape?
Frontline Fixed-Duration Therapy in CLL: Improving Outcomes and Tolerability
MinuteCE®Frontline Fixed-Duration Therapy in CLL: Improving Outcomes and Tolerability
Mutational Testing to Guide Therapy in CLL: Why and When
MinuteCE®Mutational Testing to Guide Therapy in CLL: Why and When
